Aurobindo Pharma Ltd (AUROPHARMA) Stock Forecast & Price Target

Compare

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AUROPHARMA Analyst Ratings

Hold

1 Buy

0 Hold

1 Sell

Based on 2 analysts giving stock ratings to

Aurobindo

Pharma Ltd

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AUROPHARMA Stock 12 Month Forecast

Average Price Target

₹1,190.00

▼(-0.31% Downside)

Based on 2 Wall Street analysts offering 12 month price targets for Aurobindo Pharma Ltd in the last 3 months. The average price target is ₹1,190.00 with a high forecast of ₹1,300.00 and a low forecast of ₹1,080.00. The average price target represents a -0.31% change from the last price of ₹1,193.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1024":"₹1,024","1229":"₹1,229","1434":"₹1,434","1126.5":"₹1,126.5","1331.5":"₹1,331.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.30K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1190,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.19K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1080,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.08K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1024,1126.5,1229,1331.5,1434],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1087.1,1103.476923076923,1119.853846153846,1136.230769230769,1152.6076923076923,1168.9846153846154,1185.3615384615384,1201.7384615384615,1218.1153846153845,1234.4923076923076,1250.8692307692309,1267.246153846154,1283.623076923077,{"y":1300,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1087.1,1095.0153846153846,1102.930769230769,1110.8461538461538,1118.7615384615383,1126.676923076923,1134.5923076923077,1142.5076923076922,1150.423076923077,1158.3384615384616,1166.253846153846,1174.1692307692308,1182.0846153846153,{"y":1190,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1087.1,1086.553846153846,1086.0076923076922,1085.4615384615383,1084.9153846153845,1084.3692307692306,1083.8230769230768,1083.2769230769231,1082.7307692307693,1082.1846153846154,1081.6384615384616,1081.0923076923077,1080.5461538461539,{"y":1080,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1433.17,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1390.78,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1250.55,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1346.34,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1346.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1167.37,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1053.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1224.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1132,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1128.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1075.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1025.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1087.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹1,300

Average Price Target₹1,190

Lowest Price Target₹1,080

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Damayanti Kerai

HSBC

₹1,255→₹1,300

Buy

8.91%

Upside

Reiterated

10/14/25

HSBC Reaffirms Their Buy Rating on Aurobindo Pharma Ltd (AUROPHARMA)HSBC analyst Damayanti Kerai raised the price target on Aurobindo Pharma (ARBP:IN) to INR1,300.00 (from INR1,255.00) while maintaining a Buy rating.

Alankar Garude

Kotak Mahindra

₹1,080

Sell

-9.53%

Downside

Reiterated

09/29/25

Kotak Mahindra Reaffirms Their Sell Rating on Aurobindo Pharma Ltd (AUROPHARMA)

Abdulkader Puranwala

ICICI Securities

₹1,330→₹1,300

Buy

8.91%

Upside

Upgraded

08/06/25

ICICI Securities upgrades Aurobindo Pharma Ltd (AUROPHARMA) to a Buy

Vivek Agrawal CFA

Citi

₹1,100→₹1,010

Sell

-15.39%

Downside

Reiterated

08/06/25

Aurobindo Pharma Ltd (AUROPHARMA) Gets a Sell from Citi

Shyam Srinivasan

Goldman Sachs

₹1,275→₹1,250

Buy

4.72%

Upside

Reiterated

07/15/25

Goldman Sachs Remains a Buy on Aurobindo Pharma Ltd (AUROPHARMA)

Kunal Dhamesha

Macquarie

₹1,700→₹1,010

Buy

-15.39%

Downside

Reiterated

07/08/25

Macquarie Remains a Buy on Aurobindo Pharma Ltd (AUROPHARMA)

Shrikant Akolkar

Nuvama

₹1,485→₹1,460

Buy

22.31%

Upside

Reiterated

06/27/25

Nuvama Remains a Buy on Aurobindo Pharma Ltd (AUROPHARMA)

Tushar Manudhane

Motilal Oswal

₹1,370

Buy

14.77%

Upside

Reiterated

05/28/25

Motilal Oswal Remains a Buy on Aurobindo Pharma Ltd (AUROPHARMA)

Tausif Shaikh

Exane BNP Paribas

Not Ranked

Exane BNP Paribas

₹1,311

Hold

9.83%

Upside

Reiterated

05/28/25

Exane BNP Paribas Sticks to Their Hold Rating for Aurobindo Pharma Ltd (AUROPHARMA)

Unknown Analyst

Phillip Securities

Not Ranked

Phillip Securities

₹1,600→₹1,410

Buy

18.12%

Upside

Reiterated

05/28/25

Phillip Securities Keeps Their Buy Rating on Aurobindo Pharma Ltd (AUROPHARMA)

Unknown Analyst

Prabhudas Lilladher

Not Ranked

Prabhudas Lilladher

₹1,510→₹1,440

Buy

20.63%

Upside

Reiterated

05/28/25

Prabhudas Lilladher Reaffirms Their Buy Rating on Aurobindo Pharma Ltd (AUROPHARMA)

Unknown Analyst

DAM Capital Advisors

Not Ranked

DAM Capital Advisors

₹1,560

Buy

30.69%

Upside

Reiterated

05/28/25

DAM Capital Advisors Reaffirms Their Buy Rating on Aurobindo Pharma Ltd (AUROPHARMA)

Neha Manpuria

Bank of America Securities

₹1,480→₹1,350

Buy

13.09%

Upside

Reiterated

05/27/25

Bank of America Securities Reaffirms Their Buy Rating on Aurobindo Pharma Ltd (AUROPHARMA)

Anubhav Agarwal CFA

UBS

₹1,333→₹1,200

Sell

0.53%

Upside

Reiterated

05/27/25

Aurobindo Pharma Ltd (AUROPHARMA) Gets a Sell from UBS

Kunal Lakhan

CLSA

₹1,540→₹1,400

Buy

17.28%

Upside

Upgraded

01/23/25

CLSA Upgrades Aurobindo Pharma (ARBP:IN) to Outperform (2)CLSA analyst Kunal Lakhan upgraded Aurobindo Pharma (ARBP:IN) from Hold (3) to Outperform (2) with a price target of INR1,400.00 (from INR1,540.00).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Damayanti Kerai

HSBC

₹1,255→₹1,300

Buy

8.91%

Upside

Reiterated

10/14/25

Alankar Garude

Kotak Mahindra

₹1,080

Sell

-9.53%

Downside

Reiterated

09/29/25

Kotak Mahindra Reaffirms Their Sell Rating on Aurobindo Pharma Ltd (AUROPHARMA)

Abdulkader Puranwala

ICICI Securities

₹1,330→₹1,300

Buy

8.91%

Upside

Upgraded

08/06/25

ICICI Securities upgrades Aurobindo Pharma Ltd (AUROPHARMA) to a Buy

Vivek Agrawal CFA

Citi

₹1,100→₹1,010

Sell

-15.39%

Downside

Reiterated

08/06/25

Aurobindo Pharma Ltd (AUROPHARMA) Gets a Sell from Citi

Shyam Srinivasan

Goldman Sachs

₹1,275→₹1,250

Buy

4.72%

Upside

Reiterated

07/15/25

Goldman Sachs Remains a Buy on Aurobindo Pharma Ltd (AUROPHARMA)

Kunal Dhamesha

Macquarie

₹1,700→₹1,010

Buy

-15.39%

Downside

Reiterated

07/08/25

Macquarie Remains a Buy on Aurobindo Pharma Ltd (AUROPHARMA)

Shrikant Akolkar

Nuvama

₹1,485→₹1,460

Buy

22.31%

Upside

Reiterated

06/27/25

Nuvama Remains a Buy on Aurobindo Pharma Ltd (AUROPHARMA)

Tushar Manudhane

Motilal Oswal

₹1,370

Buy

14.77%

Upside

Reiterated

05/28/25

Motilal Oswal Remains a Buy on Aurobindo Pharma Ltd (AUROPHARMA)

Tausif Shaikh

Exane BNP Paribas

Not Ranked

Exane BNP Paribas

₹1,311

Hold

9.83%

Upside

Reiterated

05/28/25

Exane BNP Paribas Sticks to Their Hold Rating for Aurobindo Pharma Ltd (AUROPHARMA)

Unknown Analyst

Phillip Securities

Not Ranked

Phillip Securities

₹1,600→₹1,410

Buy

18.12%

Upside

Reiterated

05/28/25

Phillip Securities Keeps Their Buy Rating on Aurobindo Pharma Ltd (AUROPHARMA)

Unknown Analyst

Prabhudas Lilladher

Not Ranked

Prabhudas Lilladher

₹1,510→₹1,440

Buy

20.63%

Upside

Reiterated

05/28/25

Prabhudas Lilladher Reaffirms Their Buy Rating on Aurobindo Pharma Ltd (AUROPHARMA)

Unknown Analyst

DAM Capital Advisors

Not Ranked

DAM Capital Advisors

₹1,560

Buy

30.69%

Upside

Reiterated

05/28/25

DAM Capital Advisors Reaffirms Their Buy Rating on Aurobindo Pharma Ltd (AUROPHARMA)

Neha Manpuria

Bank of America Securities

₹1,480→₹1,350

Buy

13.09%

Upside

Reiterated

05/27/25

Bank of America Securities Reaffirms Their Buy Rating on Aurobindo Pharma Ltd (AUROPHARMA)

Anubhav Agarwal CFA

UBS

₹1,333→₹1,200

Sell

0.53%

Upside

Reiterated

05/27/25

Aurobindo Pharma Ltd (AUROPHARMA) Gets a Sell from UBS

Kunal Lakhan

CLSA

₹1,540→₹1,400

Buy

17.28%

Upside

Upgraded

01/23/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aurobindo Pharma Ltd

1 Month

xxx

Success Rate

2/3 ratings generated profit

Average Return

+0.90%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +0.90% per trade.

3 Months

xxx

Success Rate

2/3 ratings generated profit

Average Return

+2.70%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +2.70% per trade.

1 Year

Shrikant AkolkarNuvama

Success Rate

2/2 ratings generated profit

Average Return

+3.55%

reiterated a buy rating 6 months ago

Copying Shrikant Akolkar's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +3.55% per trade.

2 Years

xxx

Success Rate

2/2 ratings generated profit

Average Return

+3.55%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +3.55% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AUROPHARMA Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AUROPHARMA has received 7 Buy Ratings, 0 Hold Ratings, and 2 Sell Ratings. AUROPHARMA average Analyst price target in the past 3 months is 1,190.00.

Each month's total comprises the sum of three months' worth of ratings.

AUROPHARMA Financial Forecast

AUROPHARMA Earnings Forecast

Next quarter’s earnings estimate for AUROPHARMA is ₹14.96 with a range of ₹13.10 to ₹16.40. The previous quarter’s EPS was ₹14.61. AUROPHARMA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AUROPHARMA has Performed in-line its overall industry.

AUROPHARMA Sales Forecast

Next quarter’s sales forecast for AUROPHARMA is ₹82.36B with a range of ₹80.41B to ₹83.40B. The previous quarter’s sales results were ₹82.86B. AUROPHARMA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AUROPHARMA has Performed in-line its overall industry.

AUROPHARMA Stock Forecast FAQ

What is IN:AUROPHARMA’s average 12-month price target, according to analysts?

Based on analyst ratings, Aurobindo Pharma Ltd’s 12-month average price target is 1,190.00.

What is IN:AUROPHARMA’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for IN:AUROPHARMA, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Aurobindo Pharma Ltd a Buy, Sell or Hold?

Aurobindo Pharma Ltd has a consensus rating of Hold, which is based on 1 buy ratings, 0 hold ratings and 1 sell ratings.

What is Aurobindo Pharma Ltd’s share price target?

The average share price target for Aurobindo Pharma Ltd is 1,190.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹1,300.00 ,and the lowest forecast is ₹1,080.00. The average share price target represents -0.31% Decrease from the current price of ₹1,193.7.

What do analysts say about Aurobindo Pharma Ltd?

Aurobindo Pharma Ltd’s analyst rating consensus is a Hold. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of Aurobindo Pharma Ltd?

To buy shares of IN:AUROPHARMA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Aurobindo Pharma Ltd (AUROPHARMA) Stock Forecast & Price Target

AUROPHARMA Analyst Ratings

AUROPHARMA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Aurobindo Pharma Ltd

AUROPHARMA Analyst Recommendation Trends

AUROPHARMA Financial Forecast

AUROPHARMA Earnings Forecast

AUROPHARMA Sales Forecast

AUROPHARMA Stock Forecast FAQ

Detailed List of Analyst Forecasts